Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and VEGF Expression in Esophageal Carcinoma
NCT02072720Phase 1Unknown
- Sponsor
- Amsterdam University Medical Center
- Start
- Feb 2014
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of bevacizumab in esophageal carcinoma, sponsored by Amsterdam University Medical Center. Primary endpoints: Change of VEGF mRNA expression in tumor biopsies at 5 weeks and Change of VEGFR2 phosphorylation with IHC at 8 weeks. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
esophageal carcinoma
Beyond the preview
Go deeper on NCT02072720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02072720.